The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent

EuroIntervention 2010;6:46-53 - DOI10.4244/EIJV6I1A8.

1. Mercy Angiography, Mercy Hospital, Auckland, New Zealand; 2. ICPS, Institut Cardiovasculaire, Paris Sud, Massy, France; 3. HELIOS Heart Center, Siegburg, Germany; 4. Boston Scientific Corporation, Natick, MA, USA

Aims: This first human use (FHU) study in bifurcation lesions evaluated safety and feasibility of the TAXUS Petal paclitaxel-eluting dedicated bifurcation stent.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Mitral annular reduction with subablative therapeutic ultrasound: pre-clinical evaluation of the ReCor device